Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 임우성 | * |
dc.date.accessioned | 2018-11-16T16:30:12Z | - |
dc.date.available | 2018-11-16T16:30:12Z | - |
dc.date.issued | 2018 | * |
dc.identifier.issn | 0167-6806 | * |
dc.identifier.issn | 1573-7217 | * |
dc.identifier.other | OAK-23466 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/246579 | - |
dc.description.abstract | PurposeTP53 mutation is the most common mutation in breast cancer, and it is considered a target marker of triple-negative breast cancer (TNBC). We investigated whether expression of p53 detected by immunochemical staining predicts the chemotherapy response of TNBC.MethodsA total of 11,393 TNBC patients who had between stage I and stage III enrolled in the Korean Breast Cancer Society Registry database from January 1, 2000 to December 31, 2015. There were 6,331 p53-positive (+) TNBC' patients and 5062 p53-negative (-) TNBC' patients.ResultsIn univariate analysis, p53(+) TNBC had a worse prognosis than p53(-) TNBC in patients not receiving chemotherapy (P=0.003). However, there was no difference in prognosis between p53(+) TNBC and p53(-) TNBC for patients receiving chemotherapy. In multivariate analysis adjusted for age and stage, the risk of p53(+) TNBC was 1.84 times higher than that of p53(-) TNBC in the non-chemotherapy group. However, there was no difference between p53(+) TNBC and p53(-) TNBC in patients receiving chemotherapy. In p53(+) TNBC, the risk was 0.6-fold lower when chemotherapy was administered than when chemotherapy was not administered. However, in p53(-) TNBC, there was no risk reduction effect by chemotherapy.ConclusionThe prognosis of p53(+) TNBC has worse than p53(-) TNBC, but the risk for survival was significantly reduced with chemotherapy. It suggests that p53(+) TNBC would be more sensitive to chemotherapy than p53(-) TNBC. | * |
dc.language | English | * |
dc.publisher | SPRINGER | * |
dc.subject | Triple-negative breast cancer | * |
dc.subject | Chemotherapy | * |
dc.subject | Prognosis | * |
dc.subject | P53 | * |
dc.subject | Immunohistochemistry | * |
dc.title | Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer | * |
dc.type | Article | * |
dc.relation.issue | 2 | * |
dc.relation.volume | 172 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 437 | * |
dc.relation.lastpage | 444 | * |
dc.relation.journaltitle | BREAST CANCER RESEARCH AND TREATMENT | * |
dc.identifier.doi | 10.1007/s10549-018-4928-2 | * |
dc.identifier.wosid | WOS:000447497300017 | * |
dc.identifier.scopusid | 2-s2.0-85052092591 | * |
dc.author.google | Bae, Soo Youn | * |
dc.author.google | Nam, Seok Jin | * |
dc.author.google | Jung, Yongsik | * |
dc.author.google | Lee, Sae Byul | * |
dc.author.google | Park, Byung-Woo | * |
dc.author.google | Lim, Woosung | * |
dc.author.google | Jung, Sung Hoo | * |
dc.author.google | Yang, Hsien Wen | * |
dc.author.google | Jung, Seung Pil | * |
dc.contributor.scopusid | 임우성(27167744500) | * |
dc.date.modifydate | 20240130112620 | * |